Cipla Rating
GOLDMAN SACHS ON CIPLA Maintain Neutral TGT 890 : 17.05.2021
* Goldman Sachs maintains Neutral call on Cipla after co misses its estimates in Q4
* MAINTAIN NEUTRAL TARGET: 890
* Reported Q4 Miss, Led By A 200 bps Gross Margin Impact
* Gross Margin Impacted From Shelf Stock Adjustments In US & Inventory Write-offs
* Seasonal Weakness Pronounced On Absence Of Flu Season In Both India & Key Mkts
MORGAN STANLEY ON CIPLA Maintain Overweight TGT 949 : 17.05.2021
* Morgan Stanley has an Overweight call on Cipla with a target of Rs 949/sh
* MAINTAIN OVERWEIGHT TARGET: 949
* Co Continues To Strengthen Its Base Biz In India, US & South Africa
* US Inhaler Pipeline Is Looking Deep With Several Late-stage Pdts
GOLDMAN SACHS ON CIPLA Maintain Neutral TGT 890 : 17.05.2021
* Maintain Neutral, Target at Rs 890/share
* Gross margin impact from shelf stock adjustments on gProventil in the US
* Cipla indicated that it is supplying 5x more Remdesivir units
* Cipla also sees room to improve on the current ~22.5% EBITDA margin
JPMORGAN ON CIPLA : 17.05.2021
* JPMorgan has a Neutral call on Cipla as US biz & margin disappoint
* MAINTAIN NEUTRAL TARGET: 785
* Weak Earnings As US & Margin Disappoint
* Disappointed By US Sales Despite Albuterol Ramp-up & Muted Gross Margin
* Management Guided To Maintaining Or Improving Upon The FY21 Margin Of 22%
